Why Ozempic Doesn't Work for Everyone

Why Ozempic Doesn't Work for Everyone - The Genetic Lottery You Didn't Know You Were Playing

24 min · 7. apr. 2026
episode Why Ozempic Doesn't Work for Everyone - The Genetic Lottery You Didn't Know You Were Playing cover

Beskrivelse

AI host Ben Synth explores why 1 in 7 people taking Ozempic and similar GLP-1 drugs see little to no results, examining the genetic, hormonal, and metabolic factors that determine drug response. He covers emerging pharmacogenomic research from Mayo Clinic aimed at predicting who will benefit before they start treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

Kommentarer

0

Vær den første til at kommentere

Tilmeld dig nu og bliv en del af Why Ozempic Doesn't Work for Everyone-fællesskabet!

Kom i gang

2 måneder kun 19 kr.

Derefter 99 kr. / måned · Opsig når som helst.

  • Podcasts kun på Podimo
  • 20 lydbogstimer pr. måned
  • Gratis podcasts

Alle episoder

4 episoder

episode Why Ozempic Doesn't Work for Everyone - Unpack the science behind the hype with Dr. Ben Synth cover

Why Ozempic Doesn't Work for Everyone - Unpack the science behind the hype with Dr. Ben Synth

Join Dr. Ben Synth as he uncovers the surprising science behind why Ozempic works miracles for some but fails for others. Explore the genetics, gut bacteria, and biological factors determining whether your body responds to semaglutide—or shrugs it off. An honest, evidence-based investigation into why these drugs don't work for everyone. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7. apr. 202638 s
episode Why Ozempic Doesn't Work for Everyone - The Dose You're On Probably Isn't Enough cover

Why Ozempic Doesn't Work for Everyone - The Dose You're On Probably Isn't Enough

Ben Synth examines why most Ozempic users quit within a year, uncovering the gap between clinical trial doses and real-world prescriptions. He explores cost barriers, dosing problems, side effects, and supply shortages that create apparent non-responders who were actually under-treated—revealing how healthcare system failures, not just biology, drive disappointment with GLP-1 medications. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7. apr. 202625 min
episode Why Ozempic Doesn't Work for Everyone - The Genetic Lottery You Didn't Know You Were Playing cover

Why Ozempic Doesn't Work for Everyone - The Genetic Lottery You Didn't Know You Were Playing

AI host Ben Synth explores why 1 in 7 people taking Ozempic and similar GLP-1 drugs see little to no results, examining the genetic, hormonal, and metabolic factors that determine drug response. He covers emerging pharmacogenomic research from Mayo Clinic aimed at predicting who will benefit before they start treatment. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

7. apr. 202624 min